This study compared antiretroviral activity among 6 "salvage" therapy regimens. The study was a prospective, randomized, factorial, multicenter study of the AIDS Clinical Trials 2 ϫ 3 Group. The study enrolled 277 human immunodeficiency virus (HIV)-infected patients naive to nonnucleoside analogues who had taken indinavir 16 months. The patients had 2000-200,000 HIV RNA copies/mL. Patients received saquinavir with ritonavir or nelfinavir together with delavirdine and/or adefovir and were followed for safety and antiretroviral response between baseline and week 16. At week 16, 30% (77/254) of patients had р500 HIV RNA copies/mL. Virologic response did not differ significantly between pooled ritonavir and nelfinavir groups (28% vs. 33%; ) or between pooled delavirdine and delavirdine/ad-P p .50 efovir groups (40% vs. 33%;
recommendation is supported, in part, by clinical trial data showing that most patients taking such regimens suppress HIV RNA levels for у2 years [3] [4] [5] [6] [7] [8] [9] . However, у20% of patients taking potent protease inhibitor-containing regimens on clinical trials experience virologic failure [3] [4] [5] [6] [7] [8] [9] , and the rate of virologic failure may be even higher in general clinical use [10] [11] [12] [13] [14] [15] . Current guidelines for the treatment of patients who experience virologic failure while receiving potent antiretroviral therapy are based on expert opinion [1, 2] and recommend combinations of drugs that the patient has not yet taken. Although there are some published observational data on the use of such "salvage" regimens [12, [16] [17] [18] , no published prospective, randomized clinical trial data are available.
We conducted a prospective clinical trial in a population of treatment-experienced patients with virologic failure who were taking indinavir. The patients were randomized to receive saquinavir in combination with a second protease inhibitor together with a nonnucleoside analogue reverse-transcriptase inhibitor and/or a nucleotide analogue reverse-transcriptase inhibitor.
Methods
Study design. This was a randomized, partially double-blinded, multicenter factorial study of 6 oral antiretroviral regimens that included combinations of open-label saquinavir soft gelatin cap- Table 1 . Antiretroviral study treatments.
Group
Regimen (all in mg) A Saquinavir sgc 400 bid ϩ ritonavir 400 bid ϩ delavirdine 600 bid ϩ adefovir dipivoxil placebo qd B Saquinavir sgc 400 bid ϩ ritonavir 400 bid ϩ delavirdine placebo bid ϩ adefovir dipivoxil 120 qd C Saquinavir sgc 400 bid ϩ ritonavir 400 bid ϩ delavirdine 600 bid ϩ adefovir dipivoxil 120 qd D Saquinavir sgc 800 tid ϩ nelfinavir 750 tid ϩ delavirdine 600 bid ϩ adefovir dipivoxil placebo qd E Saquinavir sgc 800 tid ϩ nelfinavir 750 tid ϩ delavirdine placebo bid ϩ adefovir dipivoxil 120 qd F Saquinavir sgc 800 tid ϩ nelfinavir 750 tid ϩ delavirdine 600 bid ϩ adefovir dipivoxil 120 qd NOTE. In addition, all patients received L-carnitine supplement, 500 mg once daily (qd). bid, 2ϫ/day; sgc, soft gelatin capsule; tid, 3ϫ/day. sules (Roche Pharmaceuticals, Nutley, NJ) with ritonavir (Abbott Laboratories, Abbott Park, IL) or nelfinavir (Agouron Pharmaceuticals, San Diego), together with blinded delavirdine (Pharmacia and Upjohn, Kalamazoo, MI) and/or adefovir dipivoxil (Gilead Sciences, Foster City, CA; table 1). The randomization was based on permuted blocks with dynamic balancing by participating site. Patients discontinued their current antiretroviral regimens, including all nucleoside analogues, and received randomized treatment for 24 weeks. Patients with geometric mean HIV RNA levels at weeks 12 and 16 of either р5000 copies/mL or у1 log 10 below baseline could continue randomized study treatment for an additional 24 weeks.
Study population. Eligible patients were у16 years old with documented HIV infection who had taken indinavir for у6 months and for 2 weeks immediately before study entry and had screening plasma HIV RNA levels of 2000-200,000 copies/mL (Amplicor HIV Monitor test; Roche Diagnostic Systems, Branchburg, NJ; lower limit of quantification, 500 copies/mL). Patients could have taken ritonavir or saquinavir hard gelatin capsule for !2 weeks but could not have taken any nonnucleoside reverse-transcriptase inhibitor, other protease inhibitors, or adefovir dipivoxil. Patients were not pregnant or breast-feeding and had not received investigational therapy within 30 days of entry.
Study procedures. Patients had visits twice before entry, at entry, at weeks 1, 2, and 4, and then every 4 weeks through week 24. At all visits, a clinical assessment and laboratory tests were done. Plasma was processed and stored at Ϫ70ЊC twice at baseline, then every 4 weeks, and was later assayed for HIV RNA in batch (baseline through week 16) at a central laboratory (University of North Carolina, Chapel Hill, or University of Washington, Seattle) with the Amplicor Monitor assay (Roche Diagnostic Systems). Specimens from weeks 16 or 24 with HIV RNA !500 copies/mL were retested with the Ultrasensitive assay (Roche Diagnostic Systems; lower limit of detection, 50 copies/mL). T lymphocyte subsets were quantified by flow cytometry twice at baseline and every 4 weeks.
Adverse events were graded by using standardized AIDS Clinical Trials Group (ACTG) guidelines from the date of entry to 30 days after permanent discontinuation of study treatment. Moderate (grade 2 or higher) intensity adverse events, including signs and symptoms and laboratory abnormalities, were recorded, to evaluate the safety and tolerability of the study treatments. In June 1998, the protocol was amended to include laboratory monitoring, toxicity management, and dose reduction of adefovir dipivoxil for proximal renal tubular dysfunction (PRTD), because of new information about the toxicity provided by Gilead Sciences. The protocol definition of PRTD was as follows: serum creatinine у0.5 mg/dL above baseline and serum phosphate !2.0 mg/dL, or 1 of these abnormalities plus 2 of the following: proteinuria (у2ϩ), glycosuria (у1ϩ) in the absence of hyperglycemia, hypokalemia (!3.0 mEq/L), or serum bicarbonate !19 mEq/L. The dose of adefovir dipivoxil (or matching placebo) was reduced to 60 mg a day after completion of 16 weeks of study. After that time, patients could continue adefovir dipivoxil or substitute or add у1 nucleoside analogues.
Interim analyses. One planned efficacy and safety interim analysis was performed in April 1998. The analysis was based on repeated confidence bands [19] and adoption of the O'Brien-Fleming spending function. A second unscheduled interim analysis focusing only on safety was undertaken in October 1998. In both analyses, the Data and Safety Monitoring Committee recommended that the trial be continued. Because of the conservative spending function, the P value for a significant result at the final analysis ( ) P p .044 was close to the nominal level, and, hence, we report the P p .05 nominal P values.
Statistical analysis. The primary study objective was to evaluate and compare the treatment regimens with respect to the proportion of patients with plasma HIV-1 RNA levels р500 copies/ mL at 16 weeks and the safety and tolerability of the regimens. Patients were to remain on their randomized treatment for 24 weeks to allow time for the processing of their weeks 12 and 16 HIV RNA levels, which were used to determine their eligibility for the open-label portion of the study. The primary comparisons focused on the 2 factors in the factorial study design: between rito-2 ϫ 3 navir and nelfinavir and among delavirdine, adefovir dipivoxil, and the combination of delavirdine plus adefovir dipivoxil. By using the factorial design, the levels of each factor were compared, after we pooled the treatment groups over the levels of the other factor. Secondary objectives included comparisons of the individual treatment groups, assessment of other virologic and immunologic responses, and durability of virologic response in patients who achieved suppression by week 16.
The sample size was determined initially as 50 patients per study arm. This yielded 150 patients per group for the comparison of ritonavir versus nelfinavir and 100 patients per group for the comparison of delavirdine, adefovir dipivoxil, or the combination. For the first of these comparisons, this yielded a power of 98% to detect a difference of 15% versus 35% in the proportion of patients who suppressed their virus loads to р500 copies/mL by week 16, based on a 2-sided test of size 0.05, allowing for a 10% dropout rate. For the second, this yielded a power of 89% to detect a difference of 15% and 35%, allowing for a 10% dropout rate. Because of a subsequent slowdown in accrual rate, the team closed the study to accrual at a total of 277 randomized patients. This slightly lowered the powers to 96% and 86%, respectively.
Efficacy analyses used an intent-to-treat approach and included all available measurements on all randomized patients. Safety analyses were based on patients who received у1 dose of study medication. Follow-up times were calculated from the randomization date. The baseline HIV RNA level was calculated as the geometric mean of the preentry and entry determinations. Baseline CD4 cell Table 2 . Baseline characteristics of the human immunodeficiency virus (HIV)-infected patients among the antiretroviral study treatment groups. tests; quantitative responses were analyzed by using the Wilcoxon rank sum test. Failure time end points were analyzed by using the Kaplan-Meier estimator and log-rank test. Regression analyses were based on simple linear regression and, in the case of binary responses, logistic regression.
Results
In total, 277 patients were enrolled between September 1997 and October 1998 at 42 units of the adult ACTG. The median length of prior indinavir use was 14 months, median baseline HIV RNA was 31,746 (4.5 log 10 ) copies/mL, and CD4 cell count was 229 cells/mm 3 . There were 13 (5%) patients with virus loads !2000 copies/mL at study entry, 99 (36%) with 2000-20,000 copies/mL, and 162 (58%) with 120,000 copies/mL. Major baseline measures were well balanced among the 6 treatment groups (table 2) . Follow-up of study patients. We followed 262 (95%) patients through at least the week 16 visit (table 3) . Two patients did not start study treatment after randomization but remained in study follow-up, 15 patients (5%) withdrew from the study before week 16, and 57 (21%) discontinued study treatment early but remained in follow-up. There were no significant differences among the groups with respect to duration of study treatment ( , log-rank test). P p . 31 HIV RNA. Median HIV RNA levels (figure 1) for all groups decreased at study weeks 4 and 8. By week 16, virus load levels trended back toward baseline levels with median virus load changes from baseline (log 10 HIV RNA copies/mL) of Ϫ0.41 (arm A; see table 1), Ϫ0.16 (arm B), Ϫ0.21 (arm C), Ϫ0.61 (arm D), Ϫ0.08 (arm E), and Ϫ0.05 (arm F). Figure 2A shows the proportion of patients with р500 HIV RNA copies/mL through week 16, by treatment group. Overall, 77 (30%) of 254 patients had р500 HIV RNA copies/mL at week 16. Arm D had the Table 3 . Disposition of the study patients among the antiretroviral study treatment groups. highest response rate of 47% (20/43 patients), compared with arm F (36%, 15/42 patients), arm A (33%, 14/42 patients), arm C (31%, 12/39 patients), arm B (20%, 9/44 patients), and arm E (16%, 7/44 patients). Of 69 patients with samples available with HIV RNA levels р500 copies/mL at week 16, 38 (55%) also had р50 copies/mL by the ultrasensitive assay. Figure 2B presents the proportion of patients with р500 HIV RNA copies/mL by week for the pooled ritonavir and nelfinavir groups. The proportions (95% pointwise confidence intervals [CIs]) of virologic suppression at week 16 were 28% (20%-36%) for ritonavir versus 33% (24%-41%) for nelfinavir ( , P p .50 Fisher's exact test). Figure 2C presents the proportion of patients with р500 HIV RNA copies/mL by week for the pooled delavirdine, adefovir dipivoxil, and combination groups. The respective proportions (95% pointwise CIs) were 40% (27%-54%) for delavirdine, 18% (7%-23%) for adefovir dipivoxil, and 33% (23%-50%) for the combination. Using 3 pairwise tests, the proportion of patients with virologic suppression for the delavirdine and combination groups was significantly greater than that of the pooled adefovir dipivoxil groups ( and .03, respec-P p .002 tively, Fisher's exact test). The difference between the delavirdine and combination groups was not significant ( , Fisher's P p .42 exact test).
Multivariate logistic regression models were used to examine the effects of baseline factors on virologic response. Patients with higher baseline CD4 cell counts (odds ratio [OR], 1.1 per 100 cells/mm 3 ; ), lower baseline HIV RNA levels (OR, P p .003 0.34 per log 10 copies/mL; ), shorter duration of prior P ! .001 indinavir use (OR, 0.93 per month; ), and female sex P p .002 (OR, 0.40; ) were significantly associated with a higher P p .04 probability of virus load levels р500 copies/mL by week 16. After we adjusted for these factors, the delavirdine groups continued to have a significantly greater virologic response rate than did the adefovir dipivoxil groups ( ) and did not P p .002 differ from the combination ( ). P p .37 Of 221 study patients with available samples, 60 (27%) had р500 HIV RNA copies/mL at week 24. Arm D had the highest response rate of 41% (15/37 patients), compared with arms C (31%, 11/36 patients), A (30%, 11/37 patients), F (22%, 8/36 patients), B (20%, 7/35 patients), and E (20%, 8/40 patients). In total, 76% of patients with р500 copies/mL of HIV RNA at week 16 with available samples remained suppressed at week (A-F) ; B, pooled ritonavir (RTV) and nelfinavir (NFV) groups; C, pooled delavirdine (DLV), adefovir dipivoxil (ADV), and combination groups. SQV, saquinavir soft gel capsules. 24 , and there were no differences between the ritonavir and nelfinavir groups ( ) or among the delavirdine, adefovir P p .57 dipivoxil, and delavirdine plus adefovir dipivoxil combination groups ( ) with respect to continued virologic suppres-P p .69 sion. Of 54 patients with samples available with HIV RNA levels р500 copies/mL at week 24, 32 (59%) had р50 copies/ mL. The available data showed that 86% of patients with HIV RNA levels р50 copies/mL at week 16 had р500 copies/mL at week 24.
CD4 cell count. (32 patients [12%] ). Forty-eight (17%) patients reported severe (grade 3 or higher) signs and symptoms (table 4). The distribution of time to first severe (grade 3 or higher) sign or symptom within the first 16 weeks of study was not significantly different between the ritonavir and nelfinavir groups ( ). However, the ritonavir groups showed a P p .071 somewhat lower rate than did the nelfinavir groups after 6 weeks of treatment by comparison of the Kaplan-Meier curves of the 2 groups for the time to the first adverse event. There were no significant differences among the delavirdine, adefovir dipivoxil, or combination groups ( ) or among the 6 P p .94 individual treatment groups ( ). P p .51 In all, 189 (68%) patients experienced moderate (grade 2 or higher) or severe (grade 3 or higher) laboratory toxicities: 87 (31%) moderate and 102 (37%) severe (table 4). Three (1%) patients experienced PRTD during the first 16 weeks-all took adefovir dipivoxil-containing regimens. The distribution of time to the first severe (grade 3 or higher) laboratory abnormality was not significantly different between the ritonavir and nelfinavir groups ( , log-rank test) but was significant P p .35 among the delavirdine, adefovir, and combination groups ( , log-rank test). The adefovir dipivoxil groups had P p .019 fewer severe or greater laboratory toxicities than did the other 2 groups. When all 6 treatment groups were compared, there was a marginally significant difference of severe or greater laboratory toxicities ( , log-rank test), and adefovir dipi-P p .062 voxil-containing groups had lower rates.
Discussion
This is the first prospective, randomized study to evaluate the virologic and immunologic activity of combination antiretroviral therapy in patients who experienced virologic failure on a protease inhibitor-containing regimen. Overall, in patients who experienced virologic failure on an indinavir-containing regimen, 77 (30%) of 254 had virus loads р500 copies/mL at week 16 (over half with р50 copies/mL) while taking a new regimen of dual protease inhibitors (saquinavir with ritonavir or nelfinavir), together with the nonnucleoside analogue reverse-transcriptase inhibitor, delavirdine, and/or the nucleotide analogue reverse-transcriptase inhibitor, adefovir dipivoxil. We found no difference in virologic response with ritonavir or nelfinavir as the second protease inhibitor but a significantly better virologic response in persons who received delavirdine instead of adefovir dipivoxil. The greatest absolute changes in virus loads occurred in the pooled delavirdine (without adefovir dipivoxil) groups. Virologic response rates for the groups receiving delavirdine plus adefovir dipivoxil were no better than in those receiving delavirdine without adefovir dipivoxil.
The virologic suppression rate demonstrated in this study is similar to rates described from observational studies in protease inhibitor-experienced patients [12, [16] [17] [18] , although one small uncontrolled study described a better response rate in nelfinavirexperienced patients who changed to a saquinavir plus ritonavir-based regimen [20] . The fact that we found in patients in whom a protease inhibitor-containing regimen failed that only a minority experienced virologic suppression on a subsequent regimen reaffirms the principle that the timing and choice of initial antiretroviral therapy are critical to avoid virologic failure. For patients who experience virologic failure, more effective "salvage" regimens are needed.
Studies of patients who had not previously taken protease inhibitors have documented the potency of dual protease inhibitor-based regimens, including saquinavir plus ritonavir [6] or nelfinavir [21] . In the current study of indinavir-experienced patients, the overall limited virologic response and the lack of a demonstrable difference in response between ritonavir and nelfinavir, used in combination with saquinavir, is likely due to significant cross-resistance among the protease inhibitors. Persons in whom the indinavir-containing regimen fails develop virus with sequential substitutions in the protease gene over 3-12 months, which confers virologic cross-resistance to other protease inhibitors [22, 23] . In the current study, a shorter duration of prior indinavir therapy was significantly associated with a more favorable virologic outcome at 16 weeks. This observation supports the principle that a change in regimen early after virologic rebound may produce a better virologic outcome. Others have noted that virologic rebound for a person on a protease inhibitor-containing regimen may not always be associated with protease inhibitor resistance [24] [25] [26] and have shown the benefit of resistance testing when selecting salvage therapy regimens [27] .
The superior virologic effect shown in the delavirdine-containing arms likely results from the fact that patients had not taken any nonnucleoside analogue reverse-transcriptase inhibitor before study entry. In a study of the combination of delavirdine with 2 nucleoside analogues, 68% of antiretroviral-naive patients suppressed HIV RNA levels at 52 weeks [28] . In addition, delavirdine is an inhibitor of cytochrome P450-mediated metabolism and can increase plasma concentrations of saquinavir [29] , ritonavir [29, 30] , and nelfinavir [31] 2-5-fold. Salvage therapy regimens should include new classes of antiretroviral agents and exploit favorable pharmacokinetic interactions, such as those of delavirdine and the protease inhibitors.
The reason for the inferior virologic effect demonstrated with adefovir dipivoxil is less clear. A study in which patients added adefovir dipivoxil to their current therapy showed a median 0.4 log 10 decrease in HIV RNA levels at 24 weeks [32] . In a subset of patients from that study who underwent intensive virologic investigation, adefovir dipivoxil had decreased activity in virus with high-level zidovudine resistance but greater activity against lamivudine-resistant virus (with the M184V substitution in the reverse transcriptase). Most patients in the current study had taken zidovudine, stavudine, and lamivudine and changed all antiretrovirals at study entry. Whether baseline high-level zidovudine resistance reduced the virologic response to adefovir dipivoxil or whether continuing therapy with lamivudine, to select virus with the M184V substitution, would enhance the virologic effect of adefovir dipivoxil is unknown.
The lack of any additive or synergistic antiviral effect with the combination of delavirdine and adefovir dipivoxil may be due, at least in part, to drug interactions among saquinavir, delavirdine, and adefovir dipivoxil. An intensive pharmacokinetic substudy conducted in 37 of the study patients indicated that, when saquinavir concentrations were compared according to the addition of reverse-transcriptase inhibitor, the area under the plasma concentration time curves (AUCs) were highest in the delavirdine arms and lowest in the delavirdine and adefovir dipivoxil combination arms [33] . In fact, saquinavir AUCs in the combination arms were reduced by ∼50%, compared with those of the delavirdine arms. There was also evidence for an interaction between delavirdine and adefovir dipivoxil, because delavirdine AUCs were significantly lower in the combination arms than in the delavirdine arms. Overall, median delavirdine concentrations were reduced by ∼50% in the combination groups, compared with the delavirdine groups. These interactions were not anticipated, and the mechanism of action is unknown. Current treatment guidelines recommend use of у2 new drugs, to which cross-resistance is not anticipated as a salvage regimen [1, 2] . However, pharmacokinetic interactions must be considered and further characterized when using complex multidrug antiretroviral regimens.
Fewer than 10% of patients discontinued study medications for toxicity. The most common adverse events were gastrointestinal symptoms, as seen in prior studies of the individual drugs [5-7, 21, 28, 32] , and the incidence did not differ among the treatment groups. Adefovir dipivoxil-related PRTD occurred in 1% of study patients during the first 16 weeks. In other studies, 35% of patients taking adefovir dipivoxil developed significant increases in serum creatinine levels, and 50% developed significant hypophosphatemia, laboratory abnormalities consistent with PRTD, by 48 weeks [32] .
In summary, one-third of patients experiencing virologic failure on an indinavir-containing regimen suppressed virus load levels when they took a new combination regimen of dual protease inhibitors, delavirdine, and/or adefovir dipivoxil. Followup of these study patients will provide more information about the durability of the viral suppression. Future studies will need to define the pharmacokinetics and virologic activity of newer antiretroviral agents and combinations of agents active against resistant strains of HIV as patients continue to experience virologic failure with current antiretroviral regimens.
